Pharmacologic strategies to modulate or enhance the effects of insulin hold particular importance for combatting psychotropic-associated weight gain
Thats the conversation rheumatology hasnt had publicly yet
The separate TRANSCEND-T2D Phase 3 program covers type 2 diabetes (TRANSCEND-T2D-1 reported topline results March 19, 2026)
Because of these uncertainties, several leading medical organizations including the American Diabetes Association and Obesity Medicine Association have recommended against using non-FDA-approved compounded GLP-1s
New Safety Signal: Dysesthesia The TRIUMPH-4 trial identified a previously unreported side effect called dysesthesia an abnormal sensation of touch where normal sensations feel unusual, uncomfortable, or mildly painful (like tingling, numbness, or "pins and needles")
Published in peer-reviewed journals